## Brilliant Violet 711™ anti-human CD8a

Catalog # / Size: 2105215 / 25 tests

2105220 / 100 tests

Clone: RPA-T8

**Isotype:** Mouse IgG1, κ

Reactivity: Human

**Preparation:** The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 711<sup>™</sup> under optimal conditions. The solution is free of unconjugated Brilliant Violet 711<sup>™</sup> and

unconjugated antibody.


**Formulation:** Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and BSA

(origin USA).

Workshop Number: **IV T171** 

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD3 FITC and CD8 (clone RPA-T8) Brilliant Violet 711™.

# **Applications:**

**Applications:** Flow Cytometry

Recommended

**Usage:** 

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet  $711^{\text{TM}}$  excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet  $711^{\text{TM}}$  is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The LEAF  $^{\rm IM}$  purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301018).

Application References:

1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New

s: York.

2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press.

#### New York.

- 3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
- 4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
- 5. Thakarl D, et al. 2008. J. immunol. 180:7431. PubMed
- 5. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
- 6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- 7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 8. Rout N, et al. 2010. PLoS One 5:e9787. (FC)

### **Description:**

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the  $\alpha_3$  domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

## Antigen References:

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.